Thymalin vs KPV: Immune Extract or Anti-Inflammatory Tripeptide, and Which One Fits

Thymalin is a polypeptide complex, a mixture of short peptides, extracted from the thymus gland of young cattle. That makes it unusual: most peptides on this site are one defined sequence a chemist can synthesize, while thymalin is a standardized extract. The group that developed it describes two dipeptides inside the mixture, Lys-Glu (KE) and Glu-Trp (EW), as the active components. The full reference is at what is thymalin.

The thymus is where T-lymphocytes mature. It is large in childhood and shrinks steadily from puberty onward, and the loss of thymic output is one of the best-described contributors to the weakening of the immune system in older age. The idea behind thymalin is to supply thymic signalling peptides to a body whose own thymus has largely stopped producing them.

Thymalin was developed in the Soviet Union by Vladimir Khavinson and Vyacheslav Morozov, working from 1973 onward at what became the St. Petersburg Institute of Bioregulation and Gerontology. It has been used clinically in Russia for decades. Almost all of its literature comes from that one group and its collaborators, much of it in Russian-language journals.

• Pushing blood stem cells toward mature T-cells. A 2020 paper in the Bulletin of Experimental Biology and Medicine exposed human hematopoietic stem cells to thymalin in culture and reported CD28, a marker of mature T-lymphocytes, rising nearly seven times while stem-cell markers fell.
• Two dipeptides acting on inflammatory genes. The developing group's 2023 paper in the International Journal of Molecular Sciences reported that thymalin and its two dipeptides reduced IL-1 beta, IL-6 and TNF-alpha production by 1.4 to 6 times in stimulated human blood immune cells.
• Calmer monocytes and macrophages. A 2022 study in the same journal, run in Italy with the St. Petersburg group as co-authors, reported reduced TNF and IL-6 in a human monocyte cell line.

All of the mechanism work is in cells.

None of the published abstracts describes randomization, blinding or placebo, and no independent group has replicated the work. There are no randomized controlled trials of thymalin. The honest framing is "used clinically in Russia for decades, with cell-study support, and without controlled trials." Detail on each claim is in thymalin benefits.

KPV is a tripeptide: lysine, proline and valine. It is the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a thirteen-amino-acid hormone the body makes. Alpha-MSH is best known for driving pigmentation, but it also works as an anti-inflammatory signal. A 2008 review in Endocrine Reviews described the three-amino-acid tail keeping much of that anti-inflammatory activity in cell and animal models, while pigmentation depends on a different part of the hormone. KPV is an attempt to keep the first role and leave the second behind. The full reference is at what is KPV.

• Getting into cells through PepT1. A 2008 paper in Gastroenterology reported that KPV is carried into intestinal cells by PepT1, the transporter the gut lining uses to absorb small peptides from food, and that its effect depended on that transporter.
• Interrupting NF-kB and MAPK. The Gastroenterology work and a 2008 paper in Inflammatory Bowel Diseases describe reduced NF-kB activation in cells and in inflamed mouse colon. NF-kB is the switch that starts transcription of inflammatory genes.
• Lower cytokine output. In cell and mouse work, less TNF-alpha, IL-6, IL-1 beta and IL-8, depending on the model.
• No pigment receptor needed. A 2012 study in human bronchial epithelial cells described KPV acting through a route independent of the melanocortin-1 receptor, which is why it is not expected to tan.

None. There are no human trials of KPV of any design. The FDA's review for its July 2026 advisory committee found no published human studies. The evidence is cell work, including human cell lines, and mouse models: several colitis studies (2008 and 2017), plus single studies in skin, airway and brain-injury models. Detail is in KPV benefits.

Thymalin suits someone whose interest is specifically immune ageing and the Russian geroprotective programme, who understands that the human evidence is observational, and who is comfortable with an animal-derived extract. It is often discussed alongside Epithalon, the synthetic peptide derived from the pineal extract studied with thymalin in the 266-person programme; see Epithalon benefits.

KPV suits inflammation-led complaints without a specific injury, most often gut-related ones, where the mouse colitis work is strongest. It is a small, defined molecule and one variable on its own, which makes it easier to judge whether it is doing anything. The wider picture for gut complaints is in peptides for gut health.

If the question is immune modulation and you want the peptide with randomized human trials, thymosin alpha-1 has them, in hepatitis B, sepsis, melanoma and vaccine response, with mixed results. The FORTIFY Blend pairs thymosin alpha-1 with KPV, BPC-157 and LL-37 for people who want immune and inflammation coverage in one vial. It is built around thymosin alpha-1, not thymalin.

They are described as doing different jobs, and some physicians prescribe more than one immune or inflammation peptide. No study has tested this combination, so it means two unknowns at once. Whether a combination fits you is worked out by your physician after reviewing your intake. Starting with one makes it easier to tell what is doing what.